Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

With a $2.47 million gift from Novo Nordisk Inc., Live HealthSmart Alabama is applying its holistic health model in Selma, ...

We recently compiled a list of the 8 Best Socially Responsible Stocks to Buy According to Hedge Funds. In this article, we ...

How might Medicare price negotiations impact Novo Nordisk's battle in the marketplace with Eli Lilly? Lilly's type 2 diabetes drug Mounjaro and obesity drug Zepbound aren't eligible for Medicare ...

Novo Nordisk is facing serious pressure from a ... thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity. For the company to continue to grow at the ...

Novo Nordisk (NVO) announced Friday that its popular ... The trial involving more than 1,400 obese adults without diabetes reached its primary endpoint as semaglutide 7.2 mg caused a statistically ...

Novo Nordisk has been able to capitalize from a sad trend as the global diabetes patients have quadrupled from 1990 to 2024. Experts expect this trend to continue as they predict another increase ...

Novo Nordisk, Other Firms Meet Danish PM to Discuss ... makes the main active ingredient in its popular obesity and diabetes injections Wegovy and Ozempic in Denmark, and exports it to the United ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk (NOVOb.CO), opens ... ingredient in its popular obesity and diabetes injections Wegovy and Ozempic in ...

CEO of Novo Nordisk, which generates more than half of its sales in the United States. Novo, which competes with U.S. drugmaker Eli Lilly, makes the main active ingredient in its popular obesity and ...